Breathing fire into targeted therapies at ASH23

In our latest Preview from the American Society of Hematology, we’re using the dragon’s…

November 30, 2023

What to watch out for at TARGETS23 – Part 2

What to watch out for in DDR, epigenetic therapies, and other hot topics

October 11, 2023

What science tells us about future directions in lung cancer

What we can learn from scientific talks at WCLC in order to improve clinical development

September 13, 2023

New Developments in Targeting Pancreatic Cancer

Important new preclinical data sets the scene for PDAC

August 30, 2023

Important and novel research to be inspired by

Highlighting some outstanding research to take note of

July 25, 2023

An under-rated gem at ASCO23

Tackling intractable cancers with a novel and creative approach to the problem

June 8, 2023

Early research which points us to new cancer therapeutic opportunities

Have you ever wondered why some anti-cancer agents do well and others poorly – even with similar…

May 11, 2023

AACR23 – is the Florida sun shining on KRAS?

Initial learnings on KRAS presentations at AACR23

April 17, 2023
The key to success in TPD

AACR23 Preview 8 – Keys to success in TPD

W2W4 on the TPD front

April 14, 2023

AACR23 Preview 4 – Stepping It Up

Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…

March 20, 2023

New directions in lymphomas

What will be the emerging products and regimens to watch out for in aggressive lymphomas?

January 31, 2023

Cracking the code to the MYC oncogene

A novel approach to targeting an intractable oncogene

January 23, 2023

Targeting MYC – trick or treat?

Beyond KRAS - targeting another of the four horsemen of the apocalypse

October 25, 2022

Going beyond PARP1/2 inhibition with novel approaches

Can we overcome resistance checkpoint blockade with novel approaches to DDR?

October 7, 2022

New directions in small cell lung cancer

A look at promising new approaches in SCLC

August 12, 2022

An alternative perspective on TIGIT

What can we learn from IO trials in lung cancer to help us evaluate TIGIT's prospects?

June 23, 2022

Winner, winner, chicken dinner!

5 key and novel early areas of development which stood out to us at AACR22

April 11, 2022

Learning from what patients tumours are telling us

Cracking the tumour code

February 4, 2022

Oncology trends and directions to watch out for in 2022

What to watch out for in 2022

January 7, 2022

Going beyond the obvious in RAS driven cancers

A dozen early stage biotechs in the RAS/RAF pathway to watch out for

November 29, 2021

New trials and tribulations in drugging KRAS mutations

A number of new developments to consider in the KRAS niche

November 12, 2021

Sticking it to MYC addicted cancers and other targets

It's time to tackle some intractable targets in oncology and elsewhere...

August 12, 2021

A bridge to a broad and deep oncology pipeline

What are Novartis up to these days with their oncology pipeline and what are they excited about?

July 29, 2021

Highlights and lowlights from the ASCO21 data drop

Which abstracts stood out in the initial run through of the data? Includes some hidden gems and surprises!

May 20, 2021

Digging deep on SHP2 and KRAS

New developments on the KRAS and SHP2 front

May 17, 2021

A twist in chemical moeity

A look at the subtleties and nuances under the hood of the Arvinas PROTACs

April 27, 2021

AACR21 Preview 3 Novel and cool approaches emerging in oncology pipelines

Emerging areas in cool new science around targeted therapies

March 18, 2021

AACR21 Preview 1 Emerging targets for protein degradation and molecular glues

What to watch out for in the protein degradation niche

March 11, 2021

Using bacteria as a trojan horse to target oncogenes

Degrading oncogenic proteins with novel bacterial approaches

March 1, 2021

Finding success in hard to treat breast cancers

Post SABCS analysis of a key topic and cancer driver

December 15, 2020

Bigging up targeted therapies at ASH 2020

W2W4 in targeted therapies at ASH20 - some key early stage areas to focus on

December 4, 2020

ASH20 Preview – Part 1 on small molecule developments

New developments in the BTK niche offer fresh insights on progress

December 1, 2020

Notes from a small island

new approaches to applying translational research to the clinic in oncology R&D

November 3, 2020

Building up a storm against resistant solid tumours

Today’s focus is on an emerging new biotech company with potential to make an impact in difficult to…

August 5, 2020

Controversial developments in pancreatic cancer

What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?

July 30, 2020

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020

The next wave of IO agents for combination therapies

Reprogramming the tumour microenvironment - can it be done and if so, how and what should be targeted?

March 12, 2020

Whipping up a frenzy in CAR-T cell future developments

In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours

February 13, 2020

The Future of Oncology R&D

Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines

January 6, 2020

10 early phase ASH19 abstracts with a difference

A look at off Broadway abstracts on early new product development and scientific findings of interest

November 26, 2019

New developments in targeting the B cell receptor pathway

It's time for an update on new participants to the runners and riders in CLL and NHL. Some interesting findings with BTK inhibitors to consider here!

November 7, 2019

Will bromodomain inhibitors and PROTACs make an impact?

A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC

September 4, 2019

Can a new class of agents therapeutically target the MYC or RAS oncogenes?

How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...

September 3, 2019

Gerard Evan discusses inflammation and immune suppression in cancer

How do mission critical oncogenes cooperate and act in concert in cancer?

August 30, 2019

Why does Myc drive out T cells?

If we want to be able to drug oncogenes such as MYC then we need to figure out how they work and function to find the achilles heel

August 29, 2019

Dancing with proteins

Proteins change shape, both temporally and also in response to different conditions. Can we use this information to develop novel cancer therapeutics? One company is exploring ways of achieving this.

May 6, 2019

How understanding patient tumours can help us with future IO trials

Looking under the hood to find biomarkers of response and outcomes, ,

June 10, 2019

On the interaction between transcription factors and the immune system

A potential role for epigenetic therapies in straddling the divide between transcription factors and the immune system...

August 26, 2019

ASH Preview 2 – Developmental Therapeutics

A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?

November 29, 2017

The BET Bromodomain Landscape in Cancer Research

The bromodomain market has exploded in recent years with many more agents in the development. Are they all the same though?

May 26, 2016

Super Enhancers – what are they and why do they matter in cancer research?

Understanding the regulatory circuitry that controls cell state and differentiation may turn out to be groundbreaking research that changes the way we think about targeting and treating cancer.

April 14, 2014

Through the window on the MYC oncogene

What can we learn about the MYC transcription factor and oncogene in order to turn it into a viable target in oncology R&D?

August 21, 2019

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019

Targeting MYC – the undruggable protein – or is it?

Targeting MYC and bromodomains is an emerging area of research as we learn more about super enhancer transcription factor clusters around oncogenes that drive cancer.

May 26, 2015